Project Grant R35GM154844
- This Project Grant award of $392,500.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports a research program at Arizona State University (ASU) focused on improving the understanding of cross-species viral transmission from wild mammals to humans. The key objectives of the five-year project are to: 1) develop automated tools to curate and maintain up-to-date taxonomic data on mammal and virus species, 2) test...
- This three-year, $1 million Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) supports the development of viral vectors for gene delivery and manipulation in amphibian research. The Trustees of Columbia University will lead efforts to design new viral vectors with host specificity for amphibians. Researchers at Columbia, the Institute of Science and Technology Austria, the University of Utah, and the Scripps Research Institute will collaborate to test...
- The University of New Mexico received a $205,869 Project Grant award from the National Science Foundation Division of Environmental Biology under the Biological Sciences federal grant program (CFDA 47.074). The grant funds collaborative research to systematically discover and characterize viral diversity across the mammalian tree of life. Researchers will sequence viruses from cryogenically frozen tissue collections of wild mammals stored in natural history museums. This will further the...
- The National Science Foundation (NSF) Division of Emerging Frontiers awarded a $613,690 Project Grant to the University of Rochester to investigate the evolution of immune investment strategies across amphibian ontogeny. The project, titled "Collaborative Research: INTBIO: The Evolution of Immune Investment Strategies Across Amphibian Ontogeny," falls under NSF's Biological Sciences (CFDA 47.074) program, which supports basic research to strengthen the nation's scientific enterprise....
- This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $232,500 to The Johns Hopkins University to investigate the virologic determinants of very early antiretroviral therapy (ART) responses in infants with in utero HIV-1 infection. The key objectives are to create infectious molecular clones from proviral HIV-1 DNA samples...
- Grant Award Summary Emory University received a Project Grant award of $860,750 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2025, through May 31, 2027. The award funds research to improve the reach and efficacy of adeno-associated virus (AAV)-based gene therapy by utilizing endogenously produced extracellular vesicles (EVs) to transport engineered transgene...
- This Project Grant award from the National Science Foundation (NSF) Biological Sciences Program (CFDA 47.074) is funding collaborative research led by Vanderbilt University to investigate how amphibian immune systems develop and adapt across life stages. The $274,765 project aims to: (1) use mathematical models and empirical data to understand how evolutionary history, pathogens, and environment influence T cell receptor diversity in frogs over ecological and evolutionary timescales; (2)...
- This Project Grant award from the National Science Foundation (NSF) Division of Emerging Frontiers, under the Biological Sciences program (CFDA 47.074), provides $388,992 to the University of Central Florida (UCF) to investigate the evolution of immune strategies across amphibian ontogeny. The key objectives are to: (1) use mathematical models and empirical data to predict when evolutionary history, pathogens, and environment favor T cell diversity within and among amphibian life stages; (2)...
- Federal Project Grant Award Summary The National Science Foundation's Division of Integrative Organismal Systems awarded $335,268 to the University of Texas at Austin under the Biological Sciences program (CFDA 47.074) for a three-year project spanning August 1, 2025 through July 31, 2028. This research initiative investigates viral proteins (specifically viral dual-specificity phosphatase 11 or VDUSP11) that enable poxviruses to evade immune defenses across diverse host species—including...
- EVOLUTIONARY AND DRUG RESISTANCE LANDSCAPE OF HUMAN TYROSINE KINASES The Pennsylvania State University received a $806,828 Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), awarded February 16, 2026, with completion targeted for January 31, 2030. This project delivers a hybrid experimental and computational research program to comprehensively predict and validate the functional effects of point mutations across the...
HOSTS GOING VIRAL: BUILDING THE TOOLS AND SYSTEMS TO DETERMINE HOW HUMAN-RELEVANT BIOLOGY EVOLVED THROUGH THE CAPTURE OF VIRAL GENES IN OUR DISTANT ANCESTORS - SUMMARY: ACQUIRING EXTRACELLULAR GENETIC AND FUNCTIONAL NOVELTY CAN FOREVER CHANGE THE EVOLUTIONARY TRAJECTORY OF ORGANISMS, FROM MITOCHONDRIA TO ANTIBIOTIC RESISTANCE TO PLACENTAL FORMATION. RETROVIRUSES HERITABLE THROUGH THE GERMLINE, ENDOGENOUS RETROVIRUSES (ERVS), COMPRISE EIGHT PERCENT OF THE HUMAN GENOME (FOUR TIMES MORE THAN PROTEIN CODING SEQUENCE). THE VAST MAJORITY OF ERVS LACK ALL PROTEIN CODING POTENTIAL. A SELECT FEW ERV GENES HAVE BEEN PRESERVED OVER EVOLUTIONARY TIMESCALES, A STRONG INDICATION THAT THESE SPECIFIC GENES ARE BENEFICIAL. ENV IS THE MOST FREQUENTLY PRESERVED ERV GENE. IN RETROVIRUSES, ENV ENCODES A GLYCOPROTEIN THAT INTERACTS WITH SPECIFIC CELLULAR RECEPTORS AND IS THE VIRUS-CELL MEMBRANE FUSOGEN. THESE ACTIVITIES HAVE BEEN REPURPOSED BY A PAIR OF ERV ENVS THAT FORM THE SYNCYTIOTROPHOBLAST, AN ESSENTIAL PLACENTAL STRUCTURE OF FUSED CELLS AT THE MATERNAL- FETAL INTERFACE. DIVERGENT ENVS HAVE BEEN COOPTED BY DIFFERENT MAMMALIAN LINEAGES FOR THE SAME FUNCTION. KNOWLEDGE OF HOW ERV GENES ARE ACQUIRED AND REPURPOSED IS LARGELY RESTRICTED TO DNA AND MRNA, WHILE IT IS TYPICALLY THE PROTEINS THAT CARRY OUT THEIR FUNCTIONS. A DEARTH OF QUALITY REAGENTS FOR ERV PROTEINS HAS IMPEDED OUR ABILITY TO DEFINE WHEN, WHERE, AND WHY THESE PROTEINS ARE EXPRESSED. WE WILL LEVERAGE OUR EXPERTISE AS EVOLUTIONARY BIOLOGISTS, PROTEIN BIOCHEMISTS, AND B CELL IMMUNOLOGISTS TO MOVE ERV RESEARCH INTO THE PROTEOME BY GENERATING, QUALITY CONTROLLING, AND DISSEMINATING THE REAGENTS REQUIRED FOR THIS TRANSITION. OUR PRIMARY FOCUS IS ENVP(B)1, AN ENV PRESERVED FOR >40 MILLION YEARS WITH NO KNOWN FUNCTION. EVOLUTION HAS MAINTAINED ITS MEMBRANE FUSION ACTIVITY ACROSS HUMAN, APE AND MONKEY ORTHOLOGS. EXPRESSION IN CULTURED CELLS RESULTS IN FUSED MONOLAYERS OF MULTINUCLEATED CELLS AND RAPID CELL DEATH. EXPRESSION IN VIVO MUST THEREFORE BE TIGHTLY REGULATED, AND ITS ACTIVITY TAILORED TO ITS FUNCTION. WE FIND GENETIC AND FUNCTIONAL EVIDENCE OF EVOLUTIONARY REFINEMENT OF ENVP(B)1 OVER THE PAST >40 MILLION YEARS. WE WILL, IN VITRO, DEFINE THE TISSUE AND SPECIES SPECIFICITIES OF MEMBRANE FUSION BY HUMAN AND NON-HUMAN PRIMATE (NHP) ENVP(B)1 ORTHOLOGS. USING ANCESTRAL RECONSTRUCTION, WE WILL DETERMINE HOW ENVP(B)1 FUNCTION EVOLVED TO ITS PRESENT FORM ACROSS PRIMATE LINEAGES. GIVEN ITS CYTOTOXICITY AND ABILITY TO PRODUCE CELLS WITH VARIABLE CHROMOSOMAL CONTENT, THE PRESERVATION OF ENVP(B)1 INDICATES IT MUST PERFORM CRITICAL FUNCTIONS. WE WILL DEFINE THE ANATOMICAL SITES AND CONTEXT OF ENVP(B)1 PROTEIN EXPRESSION IN HUMANS AND NHPS, AND IF CELL-CELL FUSION OCCURS AT THESE SITES. THIS WORK WILL ULTIMATELY ESTABLISH NHP MODELS REQUIRED TO DEFINE THE FUNCTION AND EXPLAIN WHY ENVP(B)1 IS MAINTAINED. USING A CAREFULLY CONTROLLED ANTIBODY REAGENT, WE FIND ENVP(B)1 PROTEIN EXPRESSION IN HEALTHY HUMAN AND NHP TISSUES, INCLUDING PLACENTA. THE PLACENTA, A RAPIDLY EVOLVING STRUCTURE, IS A HOTBED OF FUNCTIONAL ERV ENV EXPRESSION. WE WILL DEVELOP THE REAGENTS NEEDED TO DISSECT THE ROLES AND REGULATION OF AT LEAST EIGHT UNIQUE ERV ENVS EXPRESSED IN THIS TISSUE. THIS WORK WILL DEFINE NEW HUMAN BIOLOGY AND RAISE THE QUESTIONS OF HOW DO SPECIES WITHOUT THESE ELEMENTS DO THE SAME THING AND DO STANDARD SMALL ANIMAL MODELS FAIL TO CAPTURE THE BIOLOGY OF THESE ELEMENTS THAT ARE LARGELY PRIMATE-SPECIFIC?
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $397.5k | 4/23/25 | ||
| Not listed | $397.5k | 6/25/24 | ||
| Not listed | $397.5k | 6/25/24 |